Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Debt to Equity (2016 - 2023)

Amicus Therapeutics (FOLD) has disclosed Debt to Equity for 14 consecutive years, with $0.12 as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Debt to Equity rose 4.92% year-over-year to $0.12, compared with a TTM value of $0.12 through Jun 2023, up 4.92%, and an annual FY2022 reading of $0.17, up 183.06% over the prior year.
  • Debt to Equity was $0.12 for Q2 2023 at Amicus Therapeutics, down from $0.12 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.41 in Q2 2020 and bottomed at $0.03 in Q4 2020.
  • Average Debt to Equity over 5 years is $0.19, with a median of $0.15 recorded in 2022.
  • The sharpest move saw Debt to Equity soared 1848.22% in 2019, then tumbled 89.95% in 2020.
  • Year by year, Debt to Equity stood at $0.31 in 2019, then plummeted by 89.95% to $0.03 in 2020, then skyrocketed by 97.86% to $0.06 in 2021, then surged by 183.06% to $0.17 in 2022, then crashed by 33.04% to $0.12 in 2023.
  • Business Quant data shows Debt to Equity for FOLD at $0.12 in Q2 2023, $0.12 in Q1 2023, and $0.17 in Q4 2022.